A recent meta-analysis [8] summarized the results of three observational studies included in our review [15,22,23], highlighting how SGLT2 inhibitor use was significantly associated with a decreased risk of all-cause dementia compared to non-SGLT2 inhibitor use (RR, 0.62; 95% CI, 0.39–0.97), despite the high heterogeneity of the articles considered; in the same publication, the authors highlighted a similar benefit for DPP-4i and for GLP-1RAs, emphasizing the benefit related to general dementia, while only partial data are available for the various subtypes. This evidence concerns the gene SLC5A2 and dementia.